This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT00267527 |
|---|---|
| Status | Terminated |
| Phase | Phase 2 |
| Sponsor | ConjuChem |
| Enrollment | 120 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; HIV Infections |
| Interventions | CJC 1295 |
| Start | Dec 2005 |
| Primary completion | Not stated |
| Study completion | Sep 2006 |
| Results posted | Not yet |
| Registry last updated | Oct 16, 2006 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends. Patients will be randomly assigned to low dose CJC 1295, high dose CJC 1295 or placebo.
The objective is to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated visceral obesity.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
